Bridging the Gap in Diabetes Care: CORONA Remedies introduces affordable solution of Empagliflozin

CORONA Remedies Limited, (formerly known as CORONA Remedies Private Limited) has launched generic version of Empagliflozin introduced under the brand name “Empabite & it extensions” a SGLT-2 inhibitor, for Type 2 diabetes. With a commitment to affordability and accessibility, CORONA Remedies will offer the medication at a significantly reduced price, making it more accessible to patients.

Empagliflozin works by blocking the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. This increases the amount of glucose that is excreted in the urine, which lowers blood glucose levels. Beyond Glucose lowering property, Empagliflozin can delay Chronic Kidney Disease (CKD) and Heart failure progression in patients with or without Diabetes[1].

Commenting on the launch, Mr. Nirav Mehta, CEO & Managing Director of CORONA Remedies, stated, “At CORONA Remedies, our vision has always been ‘One world, one quality.’ We are committed to making essential medicines, affordable without compromising on global standards. We believe, the launch of our Empagliflozin, will empower many Indian patients, with access to advanced diabetes care at a reduced cost. This reinforces our dedication to public health and our mission to provide quality treatment at an affordable price.”